<DOC>
	<DOCNO>NCT00123227</DOCNO>
	<brief_summary>The purpose study determine whether rosiglitazone , peroxisome proliferator activate receptor gamma ( PPAR-gamma ) agonist , induces regression carotid atherosclerotic plaque diabetic patient vascular disease and/or hypertension 12 month period .</brief_summary>
	<brief_title>Rosiglitazone Plaque Study</brief_title>
	<detailed_description>Rosiglitazone new member thiazolidinediones ( TZDs ) , class drug act bind peroxisome proliferator activate receptor gamma ( PPAR-gamma ) . It suggest TZD class od anti-diabetic drug may exhibit anti-atherosclerotic effect . The aim study evaluate 12 month period potential benefit rosiglitazone carotid artery atherosclerotic plaque type 2 diabetic population coexist vascular disease hypertension . It hypothesise treatment rosiglitazone lead decrease plaque size . In addition hop rosiglitazone positive effect plaque composition stability . The primary endpoint plaque volume change 12 month assess cardiovascular magnetic resonance ( CMR ) . The effectiveness modality evaluate effect pharmacological agent atherosclerosis vivo demonstrate previous study use statin . The secondary endpoint define change plaque lipid content , fibrous cap thickness gadolinium enhancement measure fibrous cap inflammation plaque neovascularisation .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Patients type 2 diabetes define World Health Organization ( WHO ) criteria Male female patient 30 75 year age screen Patients coexist vascular disease ( previous myocardial infarction , cerebrovascular accident peripheral vascular disease ) hypertension ( BP &gt; 150/90 ) Patients initiated statin fibrate therapy least 6 month prior screen , receive stable dose least 3 month prior screen . [ Note : patient receive statin fibrate therapy allow enter study provide method treatment require active treatment medical condition time screen ; patient develop need statin fibrate therapy course study , therapy start without need withdraw patient study . ] Female patient must postmenopausal , surgically sterile , use effective contraceptive measure . Women childbearing age must use effective contraceptive measure least 1 month prior visit 1 ( screen ) , continue use contraceptive method study 30 day discontinue study treatment . Patients give sign informed consent participate . Patients HbA1c value &lt; 10 % screen visit . Patients evidence least one atheromatous plaque cause narrow internal carotid artery 10 95 % . Diagnosis perform prior randomisation colour duplex examination . Patients take &gt; 2 concomitant oral antihypertensive agent ( i.e . oral combination ) within 3 month prior screen visit ( visit 1 ) Previous exposure thiazolidinedione ( TZD ) PPARgamma agonist ( e.g . rosiglitazone , troglitazone , pioglitazone , GI262570 ) participation doubleblind clinical study involve TZD PPARgamma agonist randomisation code break prior visit 1 ( screen ) study . Patients require chronic use insulin glycaemic control time past ( exception need shortterm insulin use maintain glycaemic control hospitalisation , pregnancy medical procedure intervention ) patient history ketoacidosis . Use investigational drug within 30 day 5 halflives precede first dose medication start study . Systolic blood pressure &gt; 170 mmHg diastolic blood pressure &gt; 100mHg . Patients unstable severe angina congestive heart failure ( New York Heart Association [ NYHA ] class IIV ) History gangrene transient ischaemic attack ( TIA ) History stroke within previous year . Presence clinically significant hepatic disease ( i.e . patient ALT , total bilirubin , alkaline phosphatase &gt; 2.5 time upper limit normal laboratory range ) Any preexist condition clinically significant abnormality identify screening ( visit 1 ) physical examination , electrocardiogram , ultrasound examination laboratory test , judgement investigator , would preclude safe completion study . Clinically significant anaemia define haemoglobin concentration &lt; 11g/dL male , &lt; 10 g/dL female Patients creatinine &gt; 150 umol/L . Women lactate , pregnant , plan become pregnant course study . Alcohol drug abuse within last 6 month . Previous surgery carotid artery . Pacemakers , cerebral aneurysm clip , claustrophobia implantable device incompatible magnetic resonance imaging . Patients exhibit total occlusion internal carotid artery ( assessed colour duplex examination perform ) . Patients unable lie supine 60 minute .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>Randomised control trial</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Cardiovascular magnetic resonance</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Hypertension</keyword>
</DOC>